The use of predialysis glucose as long term glycemic marker in hemodialysis patients

Mustafa TOPAL; Pervin OZKAN KURTGOZ

doi:https://doi.org/10.32322/jhsm.1056046

Makale detayları

The use of predialysis glucose as long term glycemic marker in hemodialysis patients

Yazarlar:

Mustafa TOPAL | Pervin OZKAN KURTGOZ

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Health Sciences and Medicine 2022 Vol.5 Issue 2, pp.487-490

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000481572

Sıklık:

İki Aylık

eISSN:

2636-8579

DOI:

https://doi.org/10.32322/jhsm.1056046

Özet:

 

Aim: The major cause of chronic renal disease (CRD) is diabetes mellitus (DM). Although there are some other long term glycemic markers available, HbA1c remains the gold standart in CRD. In this study we aimed to explore the relation between average predialysis glucose and HbA1c levels. 
Material and Method: 101 diabetic hemodialysis patients from two centers were included in this study. Last 2 and 3 months’ average predialysis glucose levels were obtained. After 3 months, HbA1c levels were also studied. 
Results: A significant and strong correlation between HbA1c and both 2 and 3 months’ average predialysis glucose levels were found (p<0.001 and R=0.700, p<0.001 and R=0.727, The average of last 2 and respectively). Median of estimated glucose levels [146 (85-269) mg/dl] was lower than both median average of 3 months’ predialysis glucose [172.6 (80-396) mg/dl] and median average of 2 months’ predialysis glucose [180.5 (73-407) mg/dl] levels.  Hb levels were not statistically different after grouping for HbA1c ≥7% and HbA1c <7%. 
Conclusion: 3 months’ predialysis glucose levels are strongly correlated with HbA1c levels. Although there are long term glycemic markers available, average predialysis glucose is an easy, cheap and reachable method for glycemic control.

Makale detayları

The use of predialysis glucose as long term glycemic marker in hemodialysis patients

Yazarlar: Mustafa TOPAL | Pervin OZKAN KURTGOZ

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Sağlık teşvikleri

Dergi: Journal of Health Sciences and Medicine 2022 Vol.5 Issue 2, pp.487-490

Belge Tipi: Makale

Yayın Tarihi: 3/2022

Belge Dili: İngilizce

Document ID (Org No.): 2000481572

Sıklık: İki Aylık

eISSN: 2636-8579

DOI: https://doi.org/10.32322/jhsm.1056046

Sayı

Yazarlar:

Mustafa TOPAL | Pervin OZKAN KURTGOZ

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Health Sciences and Medicine 2022 Vol.5 Issue 2, pp.487-490

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000481572

Sıklık:

İki Aylık

eISSN:

2636-8579

DOI:

https://doi.org/10.32322/jhsm.1056046